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One Sentence Summary: Although TSLP, IL-25, and IL-33 have emerged as important 27	
initiators of type 2 immunity, combined blockade of all three mediators may be needed to treat 28	
some forms of progressive type 2 cytokine driven inflammation and fibrosis. 29	
 30	
Abstract: Thymic stromal lymphopoietin (TSLP), IL-25, and IL-33 are important initiators of 31	
type 2-associated mucosal inflammation and immunity.  However, their role in the maintenance 32	
of progressive type 2 inflammation and fibrosis is much less clear.  Here, using chronic models 33	
of helminth infection and allergic lung inflammation, we show that collective disruption of 34	
TSLP, IL-25, and IL-33 signaling suppresses chronic and progressive type 2 cytokine-driven 35	
inflammation and fibrosis.  In a schistosome lung granuloma model or during chronic S. mansoni 36	
infection in the liver, individual ablation of TSLP, IL-25, or IL-33/ST2 had no impact on the 37	
development of IL-4/IL-13-dependent inflammation or fibrosis.  However, significant reductions 38	
in granuloma-associated eosinophils, hepatic fibrosis, and IL-13-producing group 2 innate 39	
lymphoid cells (ILC2s) were observed when signaling of all three mediators was simultaneously 40	
disrupted.  Combined blockade via mAb treatment also reduced IL-5 and IL-13 expression 41	
during primary and secondary granuloma formation in the lung. In a model of chronic house dust 42	
mite-induced allergic lung inflammation, combined mAb treatment did not decrease established 43	
inflammation or fibrosis. TSLP/IL-33 double-knockout mice treated with anti-IL-25 mAb during 44	
priming, however, displayed decreased inflammation, mucus production, and lung remodeling in 45	
the chronic phase. Together, these studies reveal partially redundant roles for TSLP, IL-25, and 46	
IL-33 in the maintenance of type 2 pathology and suggest that in some settings, early combined 47	
targeting of these mediators is necessary to ameliorate progressive type 2-driven disease. 48	
 49	
Main Text: 50	
 51	
Introduction 52	
 53	
Type 2 immunity is characterized by the production of the cytokines IL-4, IL-5, IL-9, and 54	
IL-13, which play diverse roles in the immune response (1).  In addition to suppressing the pro-55	
inflammatory activity of type 1 immune responses (2), type 2 immunity regulates wound healing 56	
(3), metabolic homeostasis (4), and immunity to several extracellular parasites (5).  However, 57	
while the type 2 response exhibits many host protective functions, should these responses persist 58	
or become dysregulated, they can contribute to the development of disease.  Chronic type 2 59	
cytokine production underlies diseases including allergic asthma, atopic dermatitis, allergic 60	
rhinitis, ulcerative colitis, and many chronic fibroproliferative disorders (6-9).  Therefore, a 61	
better understanding of the mechanisms that regulate the initiation, maintenance and resolution 62	
of type 2 immune responses could reveal novel approaches to treat a host of important human 63	
diseases. 64	
 Three predominantly epithelial cell-derived cytokines: thymic stromal lymphopoietin 65	
(TSLP), IL-25, and IL-33, have emerged as important initiators of type 2 immunity in mammals, 66	
and their expression during type 2 disease in humans is widely-documented (10-15).  These 67	
alarmins are released from the epithelium and other local stromal compartments when cells are 68	
damaged or stressed by allergens, pollutants or pathogens and thereby trigger the production of 69	
the canonical type 2 cytokines IL-5, IL-9, and IL-13 by human and mouse cells of the innate and 70	
adaptive immune system (16, 17).  TSLP targets dendritic cells (DCs), basophils, mast cells, 71	
monocytes, natural killer T cells, and type 2 innate lymphoid cells (ILC2s) (18-21).  In humans, 72	
TSLP has been shown to induce naïve human CD4+ Th2 cell responses, but only in the presence 73	
of DCs (22).  IL-25 and IL-33 exhibit similar Th2-inducing activity, but rather than targeting 74	
DCs, myeloid cells, and Th2 cells, they largely promote type 2 immunity by stimulating ILC2s 75	
as well as basophils, mast cells, and eosinophils. IL-33 will amplify antigen-dependent and -76	
independent effector responses from both human and mouse Th2 cells (16, 17).  One recent 77	
study revealed that IL-33 can enhance TSLP and DC-mediated human Th2 memory responses in 78	
vitro suggesting the alarmins could play a role in maintaining immune responses (23).  Although 79	
TSLP, IL-25, and IL-33 have all been shown to promote type 2 immunity when overexpressed in 80	
mice (10-12), the requirement for these cytokines in the development of type 2 immunity in 81	
response to allergens and helminth parasites has been more variable, with some studies 82	
identifying little to no role for TSLP, IL-25, or IL-33 when targeted individually (24-28).  This 83	
variability has been attributed to the redundant and overlapping functional activities of these 84	
cytokines.  IL-33 and IL-25 have both been shown to induce production of IL-13 by human ILCs 85	
in vitro, for example (29).  However, this theory has not been systematically investigated in vivo, 86	
nor have the combined roles of the 3 cytokines been dissected in models of chronic type 2-87	
dependent disease.  88	
 In the present study, we utilized both genetic- and monoclonal antibody-based strategies 89	
to investigate whether bi-functional or tri-functional targeting of TSLP, IL-25, and IL-33-90	
dependent signaling more effectively controls pathogenic Th2 responses than disrupting any of 91	
the pathways individually.  The roles of the 3 cytokines in the initiation and maintenance of 92	
primary and secondary type 2 immune responses were investigated in both acute and chronic 93	
models of lung inflammation and during chronic helminth infection.  These models involve 94	
innate-initiated pathways as well as the development of antigen-specific T cell responses that 95	
influence outcomes at later stages.  A major goal was to investigate if type 2 cytokine-driven 96	
inflammation and fibrosis could be ameliorated more effectively if all three epithelial cytokines 97	
were targeted in combination.  Moreover, in contrast to previous studies that have focused on 98	
their role in the “initiation” of type 2 immunity (30), our studies were also designed to 99	
investigate if TSLP, IL-25, and IL-33, either alone or in combination, are required for the 100	
“maintenance” of established type 2-driven disease, as this is the stage where most therapeutic 101	
strategies are initiated.     102	
 103	
Results 104	
 105	
Function of IL-25 during the initiation and maintenance of type 2 inflammation 106	
We have previously shown that TSLP is not required for type 2-driven granuloma formation and 107	
fibrosis induced by the eggs of the helminth parasite Schistosoma mansoni (26).  Another group 108	
has demonstrated that many helminths could bypass the need for TSLP in the development of 109	
type 2 responses by directly modulating dendritic cell function (28).  However, the relative 110	
importance of IL-25 and IL-33 to the maintenance of established type 2-driven disease and the 111	
potential redundancy of these mediators has not been assessed.  Therefore, we began by 112	
exploring the contribution of IL-25 in type 2-dependent inflammation and fibrosis by 113	
overexpressing IL-25 in mice that were injected i.v. with live S. mansoni eggs.  Hydrodynamic 114	
delivery of an IL-25-expressing plasmid to naïve mice boosted IL-25 mRNA expression more 115	
than 1000-fold in the liver (Fig. 1A).  As observed in previous studies (10), corresponding 116	
increases in IL-4, IL-5, and IL-13 expression were observed in both the liver and the lung (Fig. 117	
1A).  When the IL-25-expressing plasmid was delivered 24 hours prior to exposure to S. mansoni 118	
eggs, the resulting granulomatous response to the eggs in the lung was exacerbated (Fig. 1B).  119	
Indeed, granuloma volume more than doubled in the IL-25 pre-treated mice, and their lesions 120	
contained many more eosinophils than control mice, which was likely due to type 2 cytokine 121	
induction in the lung (Fig. 1C).  Goblet cell hyperplasia and mucus production were also 122	
augmented in lungs of mice treated with the IL-25 plasmid.  The effects of IL-25 plasmid 123	
administration were reduced in IL-13Rα-/- mice, demonstrating that the IL-25-mediated 124	
increase in type 2-associated pathology was dependent on IL-4/IL-13-mediated signaling through 125	
the type II IL-4 receptor complex (Fig. 1B).  Eosinophils accumulated following plasmid 126	
administration, however, likely explained by IL-25-driven IL-5 expression (Fig. 1C). 127	
 Although these studies established that IL-25 could exacerbate type 2 cytokine-driven 128	
pathology, they did not reveal whether endogenously expressed IL-25 was critical to the 129	
development of granulomatous inflammation and fibrosis.  To clarify the role of IL-25 in both 130	
the initiation and maintenance of type 2-driven fibrosis, we used IL-25-/- mice in both primary 131	
(like Fig. 1B) and secondary i.v. S. mansoni egg challenge models (31).  In these experiments, 132	
naïve or egg-sensitized IL-25-/- mice and wild-type littermates were challenged i.v. with live S. 133	
mansoni eggs and granuloma formation was quantified on day 7 post-challenge.  Neither primary 134	
nor secondary granuloma formation was significantly reduced in the absence of IL-25 (Fig. 1D). 135	
The number of granulomatous eosinophils in each group was also indistinguishable during both 136	
primary and secondary challenges (Fig. 1D, right panel).  Finally, to evaluate the requirement 137	
for IL-25 in a more chronic type 2 disease setting, we exposed wild-type and IL-25-/- mice to S. 138	
mansoni cercariae and quantified granuloma volume, tissue eosinophilia, and fibrosis in the liver 139	
after 12 weeks of infection.  Similar to the results in the lung (Fig. 1D), no significant change in 140	
type 2-dependent pathology was observed in livers of IL-25-/- mice compared with wild-type 141	
mice when chronically infected with S. mansoni (Fig. 1E).  142	
 143	
Role of IL-33 in type 2 inflammation and fibrosis 144	
Given that the inflammation and fibrosis induced by S. mansoni eggs in both the lung and liver 145	
were IL-4-, IL-13-, and IL-13Rα-dependent but did not require IL-25 or TSLP (26), we next 146	
examined whether IL-33/ST2 receptor signaling was required in this setting.  As observed in IL-147	
25-/- mice, mice deficient in IL-33 showed no significant reduction in either primary (Fig. 2A) or 148	
secondary granuloma formation (Fig. 2B) when challenged i.v. with live S. mansoni eggs.  In 149	
both models, type 2-driven fibrosis and eosinophilia were similar in wild-type and IL-33-/- mice.  150	
We also infected wild-type and IL-33-/- mice with S. mansoni cercariae and examined the 151	
development of type 2-dependent pathology in the liver at acute (week 9) and chronic (week 12) 152	
phases of infection.  Although recent studies using hepatotoxic chemicals or schistosome egg-153	
driven models have suggested that IL-33 expression is critical to the development of fibrosis in 154	
the liver (32), we observed no reduction in hepatic fibrosis in IL-33-/- mice at either time-point 155	
(Fig. 2C) and picrosirius red staining of liver sections (Fig. 2D).  The number of eosinophils in 156	
the lesions and the diameter of granulomas were also similar in the absence of IL-33, confirming 157	
unimpaired type 2-driven inflammation (Fig. 2E).  The marked type 2 cytokine response that 158	
normally develops in the livers of infected wild-type mice was also similarly observed in IL-33-/- 159	
mice, and in the case of IL-4 expression was even slightly increased (Fig. 2F), further suggesting 160	
that IL-33 signaling is dispensable for the development of type 2 cytokine-driven pathology 161	
during both acute and chronic S. mansoni infection.  162	
 163	
Disrupting TSLP, IL-25, and IL-33 signaling during S. mansoni infection 164	
To investigate whether TSLP, IL-25, and IL-33 were playing redundant roles in the maintenance 165	
of type 2 cytokine-dependent granuloma formation and fibrosis, we developed strategies to 166	
disrupt all three cytokine pathways simultaneously.  In initial studies, TSLP-/- mice were crossed 167	
with IL-33-/- mice to generate a double knockout mouse, and a highly effective neutralizing mAb 168	
was introduced to the double knockout mice to block IL-25.  C57BL/6 mice were infected with 169	
S. mansoni cercariae, and the response in the absence of TSLP, IL-25, and IL-33 signaling was 170	
evaluated at acute (week 9) and chronic (week 12) phases of infection.  We first measured TSLP, 171	
IL-25, and IL-33 gene expression and found each gene is constitutively expressed in whole liver 172	
tissue at detectable levels (Fig. S1).  These levels of expression do not change significantly 173	
during S. mansoni infection on a whole tissue level.  In contrast to the studies in which individual 174	
cytokines were targeted, we observed a small yet significant decrease in granuloma volume in 175	
the triple deficient mice in the acute phase (Fig. 3A).  This was also accompanied by a 25-30% 176	
decrease in hepatic fibrosis (Fig. 3B) and a small yet significant decrease in the number of 177	
granuloma-associated eosinophils (Fig. 3C).  Interestingly, the decrease in pathology observed at 178	
week 9 was associated with a significant decrease in the frequency of IL-13-producing type 2 179	
innate lymphoid cells (ILC2s) in the mesenteric lymph nodes (MLNs) (Fig. 3D), which is 180	
consistent with the ILC2-promoting activity of IL-25 and IL-33 (33).  The frequency of ILC2s in 181	
the liver, however, was not significantly different between the two groups (Fig. 3D, right 182	
panel).  Total leukocyte numbers were similar in the liver tissue and MLNs of both cohorts. 183	
By 12 weeks post-infection, the decrease in IL-13-producing ILC2s in MLNs observed at 184	
week 9 was no longer significant (Fig. 3D, left panel), and while there was a modest but 185	
consistent decrease in pathology at week 9, granuloma volume and fibrosis became 186	
indistinguishable between WT and DKO + αIL-25-treated mice (Figs. 3A-C).  Indeed, both 187	
groups of mice displayed a striking increase in IL-13-dependent fibrosis by week 12 as 188	
determined by both hydroxyproline assay (Fig. 3B) and picrosirius red staining (Fig. 3E).  In 189	
addition, while the frequency of IL-13-producing ILC2s was lower in the MLN at week 9 (Fig. 190	
3D), a marked increase in IL-4- and IL-13-producing CD4+ T cells was observed at the same 191	
time point in the granulomatous livers of the DKO + αIL-25-treated mice (Fig. 3F).  Antigen-192	
specific CD4+ Th2 cell cytokine production likely compensated for the transient decrease in 193	
ILC2s, thus explaining the unimpaired development of IL-13-dependent fibrosis in triple 194	
deficient mice by week 12.  195	
 196	
Disrupting TSLP, IL-25, and IL-33 signaling during acute granuloma formation 197	
 After considering the transient nature of immune control affected by disrupting the three 198	
mediators during S. mansoni infection, we hypothesized that the effect of blocking all three 199	
cytokines would be more apparent when applied to a more acute model where the cytokines are 200	
blocked from the onset of injury.  Primary and secondary lung granuloma models were employed 201	
for these studies because they provide simple and short-term systems to dissect the importance of 202	
TSLP, IL-25, and IL-33 during both the sensitization and maintenance phases of a type 2 203	
cytokine-driven inflammatory response (31).  Groups were treated with either isotype control 204	
antibodies or with αTSLP, αIL-25αST2 (IL-33 receptor) monoclonal neutralizing 205	
antibodies for the entire length of the experiments.  The pathological effects of TSLP, IL-25, and 206	
IL-33 have been directly linked to the enhanced production of IL-4, IL-5, and IL-13 by 207	
downstream target cells such as CD4+ Th2 cells, ILC2s, and other innate lymphocytes (33, 34), 208	
and much of the pathology that results from the persistent activation of type 2 immunity has been 209	
attributed to IL-4/IL-13-mediated signaling through the IL-4 receptor (35).  Therefore, we used 210	
IL-4RГ-deficient mice as positive controls.  211	
Surprisingly, as observed in previous lung granuloma studies where TSLP, IL-25, and IL-212	
33 were targeted individually, the combined blockade of all three cytokines had no significant 213	
impact on the volume of the lesions in mice undergoing either primary (Fig. 4A) or secondary 214	
(Fig. 4B) granuloma formation.  In marked contrast, the lesions in IL-4Rα–/– mice were about 215	
50% smaller than those in isotype control treated mice (Figs. 4A-B).  The triple blockade did 216	
lead to a >80% reduction in the number of granuloma-associated eosinophils during primary 217	
granuloma formation (Fig. 4A, right panel and tissue sections).  Macrophages and primarily 218	
lymphocytes comprised the granulomas in the absence of eosinophils.  Nevertheless, the 219	
eosinophil deficit in the triple blockade mice was completely corrected when the mice were 220	
undergoing a secondary challenge (Fig. 4B, right panel and tissue sections).  IL-4Rα-/- mice, in 221	
contrast, displayed a near complete absence of eosinophils following both primary and secondary 222	
challenges. 223	
 Although the effects of the triple blockade on egg-induced pathology were minimal, there 224	
were notable changes in cytokine expression in the lungs.  Triple blockade mice displayed 225	
significant reductions in IL-4, IL-5, and IL-13 expression in the lung during primary granuloma 226	
formation (Fig. 4C) and in IL-5 and IL-13 during secondary granuloma formation (Fig. 4D).  It 227	
is worth noting that while these measurements imply a significant reduction in the type 2 228	
cytokines following triple blockade, they were expressed at significantly higher levels than that 229	
in IL-4Rα–deficient mice.  Interestingly, changes in expression of two eosinophilic chemokines, 230	
Ccl5 and Ccl11, do not explain the eosinophil phenotype we observed.  Ccl5 and Ccl11 were not 231	
affected by the triple blockade during the primary response (Fig. 4C) although both chemokines 232	
were reduced in the triple blockade mice during a secondary response (Fig. 4D).  Rather, the 233	
pattern of Il5 gene expression likely explains why granuloma eosinophilia is reduced by the 234	
triple blockade during primary granuloma formation and is restored during secondary granuloma 235	
formation.  The reduced Il5 expression in triple blockade mice during primary granuloma 236	
formation was on par with expression observed in IL-4Rα -deficient mice.  During secondary 237	
granuloma formation, Il5 expression was reduced by the triple blockade, but it was still 238	
expressed at significantly higher levels than in IL-4Rα –deficient mice.   239	
As seen in many type 2 cytokine-driven diseases, we observed increased Il33, Tslp, and 240	
Il25 gene expression in the lungs of wild-type mice in the primary granuloma model (Fig. 4C).  241	
While gene expression of Il33 and Tslp increased in the lungs of mice undergoing secondary 242	
granuloma formation, Il25 was expressed at baseline levels during the secondary response (Fig. 243	
4D). The increase was IL-4R-dependent as Il33 and Tslp expression diminished to baseline 244	
levels in IL-4Rα-/- mice.  We hypothesize the low alarmin expression in IL-4Rα-/- mice is due to 245	
decreased inflammation-driven injury in these mice.   246	
Together, our studies with S. mansoni demonstrated that TSLP, IL-25, and IL-33 play 247	
redundant roles in the maintenance of chronic type 2 immunity.  More importantly, targeting all 248	
three cytokines simultaneously from the initiation of primary or secondary granuloma formation 249	
reduced type 2 cytokine production but offered little protection from egg-induced pathology.  250	
 251	
Efficacy of TSLP, IL-25, and ST2 blockade on established chronic allergy 252	
With evidence that the combined blockade of TSLP, IL-25, and IL-33 signaling had a significant 253	
impact on type 2 cytokine expression, we hypothesized that the triple blockade might ameliorate 254	
type 2-mediated pathology in a different disease model.  We sought to investigate a model that 255	
primarily targets epithelial cells, the predominant source of TSLP, IL-25, and IL-33, to 256	
determine whether the maintenance of type 2 immunity induced via mucosal epithelial injury 257	
was more dependent on the targeted cytokines.  We chose to test the effects of administering 258	
single, double, and triple mAb blockades to a model of house dust mite (HDM)-induced allergic 259	
inflammation entering its chronic stage.  Genes for all three alarmins are expressed at steady 260	
state in the lung, and HDM induces expression of each of the alarmins with complementary 261	
kinetics (Fig. S2).  Il33 was upregulated acutely and at chronic stages of allergic disease.  Tslp 262	
was only upregulated in the initial hours after first HDM exposure, and Il25 was upregulated 263	
only at chronic time-points.  BALB/c mice were chronically challenged i.n. with HDM on days 264	
0, 7, and 14 and then received eight additional doses spread over a total of 45 days.  Beginning 265	
three weeks after the initiation of the allergic response, separate groups of HDM-treated mice 266	
were administered doses of anti-ST2, anti-TSLP, anti-IL-25 every 3 to 4 days in various 267	
combinations to achieve single, double, or triple blockades.  Additional control groups received 268	
either saline or isotype control antibodies with or without HDM.  On day 46, all mice were 269	
analyzed.  As expected, in the lungs of isotype-treated control mice, chronic HDM exposure 270	
resulted in a marked increase in inflammatory cells in the lung (Fig. 5A) and nearly a two-fold 271	
increase in collagen content (Fig. 5B), confirming extensive lung remodeling and fibrosis.  272	
Surprisingly however, none of the single, double, or triple blockade combinations led to a 273	
significant decrease in inflammation or fibrosis in the sensitized mice.  When the triple blockade 274	
mice were analyzed more closely, we also observed little to no change in the type 2 cytokine 275	
response in the lung (Fig. 5C), and the total number of leukocytes in the BAL and lung appeared 276	
indistinguishable between the triple blockade and isotype control treated mice (Fig. 5D).  We 277	
did, however, observe a significant decrease in the percentage of eosinophils in the lung but not 278	
in the BAL (Fig. 5E).  279	
 280	
Disrupting TSLP, IL-33, and IL-25 signaling during initiation and maintenance of type 2-281	
driven chronic allergy 282	
The failure of the triple blockade to protect against type 2-driven pathology when applied to 283	
established allergy further suggested that TSLP, IL-25, and IL-33 are not critical for the 284	
maintenance of chronic type 2 driven allergic lung inflammation.  To test whether disrupting 285	
signaling of the three cytokines during the initiation of type 2 cytokine-driven allergic lung 286	
inflammation provides a benefit, in a final series of experiments, IL-33/TSLP DKO mice were 287	
treated with anti-IL-25 during the entire course of chronic HDM exposure.  Here, the deficient 288	
mice displayed marked and significant decreases in fibrosis when compared with control HDM 289	
mice on day 46 (Fig. 6A).  Although peribronchial and perivascular inflammation in the lung 290	
was similar in both groups, we observed a marked decrease in endarteritis and mucus staining in 291	
the lumen of the deficient mice (Fig. 6B).  In addition, the total number of BAL cells (Fig. 6C), 292	
and the number of eosinophils in the BAL (Fig. 6D) and lung (Fig. 6E) were reduced.  The 293	
decrease in inflammatory eosinophils was also accompanied by a marked and highly significant 294	
reduction in IL-4, IL-5, and IL-13 production in the lung (Fig. 6F) and IL-13 and IL-5 were also 295	
significantly decreased in the BAL (Fig. 6G).  We observed similar results using anti-ST2, anti-296	
TSLP, anti-IL-25 neutralizing antibodies in wild-type mice during the entire course of chronic 297	
HDM exposure (Fig. S3). 298	
 299	
Discussion 300	
 301	
Although TSLP, IL-25, and IL-33 have each been identified as important initiators of 302	
type 2 immunity, their role in the maintenance of progressive type 2 disease was much less clear.  303	
In the present study, using chronic models of helminth infection and type 2 cytokine-driven lung 304	
inflammation, we found that tri-functional targeting of TSLP, IL-25, and IL-33 was more 305	
efficacious than blocking any one of the mediators alone.  This conclusion is strengthened since 306	
we made the observations using mice on both C57BL/6 and BALB/c backgrounds.  In a 307	
schistosome lung granuloma model or during chronic S. mansoni infection in the liver, selective 308	
ablation of TSLP, IL-25, or IL-33/ST2 had little to no impact on the development of IL-4/IL-13-309	
dependent inflammation or fibrosis.  Nevertheless, we observed modest albeit significant 310	
reductions in egg-induced inflammation in the liver when signaling of all three mediators was 311	
disrupted simultaneously. The reduction in inflammation in the schistosome infection model was 312	
also accompanied by a small yet significant decrease in the number of granuloma-associated 313	
eosinophils, a 25-30% decrease in hepatic fibrosis, and a significant reduction in the number of 314	
IL-13-producing ILC2s in the mesenteric lymph nodes.  The deficient mice also displayed 315	
reduced expression of IL-5 and IL-13 during primary and secondary granuloma formation in the 316	
lung.  Furthermore, when signaling of all three mediators was disrupted in a model of chronic 317	
HDM-induced allergic lung inflammation, inflammation, mucus production, and lung 318	
remodeling were decreased.  Together, these studies revealed redundant roles for TSLP, IL-25, 319	
and IL-33 in the maintenance of these type 2-associated pathologies and suggest that aggressive 320	
tri-functional targeting of these mediators may more effectively ameliorate progressive type 2-321	
driven disease. 322	
 Previous studies identified critical roles for TSLP, IL-25, and IL-33 in type 2 immunity to 323	
some helminth parasites (36-43).  However, the majority of these studies have focused on 324	
Nippostrongylus brasiliensis infection, in which expulsion of the nematode parasite is delayed or 325	
accelerated by relatively minor changes in type 2 immunity. Our initial studies focused on the 326	
schistosome lung granuloma and S. mansoni infection models because these models provide 327	
robust systems to dissect the role of TSLP, IL-25, and IL-33 during both the initiation and 328	
maintenance phases of type 2-driven inflammation (31). As reported previously with TSLP (26), 329	
we observed little to no role for IL-25 or IL-33 in IL-4/IL-13-dependent granuloma formation in 330	
the lung.  A recent study found modest decreases in acute inflammation in the absence of IL-25 331	
(44), but in our studies, IL-25 or IL-33 deficiency alone had no discernable impact on the 332	
development of type 2 immunity or type 2-dependent pathology, even during the initiation of a 333	
primary granulomatous response.  A similar outcome was observed in the liver following acute 334	
and chronic infection with S. mansoni, suggesting that TSLP, IL-25, and IL-33 were either not 335	
required or were possibly playing redundant roles (26, 28, 38, 45).  Importantly, although we 336	
found little to no role for TSLP, IL-25, or IL-33/ST2 when each mediator was ablated 337	
individually, we observed significant reductions in type 2 inflammation and fibrosis in the liver 338	
when all three mediators were targeted simultaneously, confirming their overlapping activities in 339	
response to significant damage during acute schistosomiasis.  It is possible the degree of damage 340	
from parasites and other environmental triggers may impact the redundancy of the alarmins.  341	
Also, schistosome egg antigens have been identified that are capable of directly activating type 2 342	
responses by modulating dendritic cell function(46, 47).  Basophil- and autocrine T cell-derived 343	
IL-4 may also be sufficient to initiate and maintain type 2 responses(48, 49).  Therefore, alarmins 344	
may not be critical to the activation or maintenance of all type-2 cytokine driven inflammatory 345	
responses. 346	
 The type 2 response is a critical driver of wound repair pathways (1).  However when 347	
type 2 cytokine production persists or becomes dysregulated, it can lead to the development of 348	
pathological fibrosis (3).  Consequently, because of their type 2-inducing activity, there has been 349	
a great deal of interest in understanding the roles of TSLP, IL-25, and IL-33 in progressive 350	
fibrosis, with numerous studies identifying increased production of these cytokines in various 351	
fibrotic diseases (50-54).  Many recent studies have shown that when overexpressed in mice, 352	
TSLP, IL-25, and IL-33 induce fibrosis in multiple tissues.  For example, IL-25 was shown to 353	
promote lung remodeling in a model of house dust mite induced allergic airway disease and 354	
indirectly induced pulmonary fibrosis by stimulating the production of IL-13 from ILC2s (44, 355	
54). Transgenic overexpression of IL-33 has also been shown to promote IL-13-dependent 356	
cutaneous fibrosis (55), ILC2-mediated hepatic fibrosis (32), and bleomycin-induced pulmonary 357	
fibrosis in mice (56). Transgene-induced expression of TSLP has also been shown to induce 358	
pulmonary fibrosis in the lung by upregulating type 2 cytokine expression (52).  Nevertheless, 359	
evidence that these epithelial-derived alarmins are critical to the development of Th2-associated 360	
fibrosis in a natural model of fibrosis was lacking prior to this study. Our studies with the 361	
schistosome lung granuloma and infection models show quite unequivocally that IL-13-362	
dependent fibrosis can develop in the lung and liver independently of TSLP, IL-25, and IL-33. 363	
We did, however, observe a significant decrease in fibrosis when all three mediators were 364	
targeted simultaneously, with the reduction in fibrosis associated with a significant decrease in 365	
IL-13 producing ILC2s. Surprisingly, at more chronic time points following infection with S. 366	
mansoni the early reduction in fibrosis and ILC2 activity appeared to be compensated for by an 367	
increased CD4+ T cell-derived IL-13 response, suggesting that TSLP, IL-25, IL-33 and ILC2s 368	
may not be critical to the maintenance of established and progressive fibrosis once the adaptive 369	
immune response has taken over.  The relative involvement of an adaptive antigen-specific 370	
response may therefore be important in determining the relative contribution of these innate 371	
pathways to chronic disease.  Regardless, these data further emphasize the potential benefit of 372	
early combinatorial targeting of TSLP, IL-25, and IL-33 in the treatment of type 2-driven 373	
disease.   374	
 Because epithelial cells are a major source of TSLP, IL-25, and IL-33 and schistosome 375	
eggs primarily damage the endothelium, it is possible that these cytokines are less important to 376	
the development of type 2 pathology in schistosomiasis.  Therefore, in a final series of 377	
experiments, we utilized a chronic model of HDM-induced allergic lung inflammation to explore 378	
the combined roles of TSLP, IL-25, and IL-33 in a disease where the epithelium is the primary 379	
target.  Here, in contrast to the lung granuloma studies in which a mAb triple blockade 380	
administered from initial egg challenge had little impact on type 2 pathology, disrupting TSLP, 381	
IL-25, and IL-33 signaling from first allergen exposure had a significant suppressive effect on 382	
the development of fibrosis, endarteritis, and mucus deposition in the lumen.  The number of 383	
inflammatory cells in the BAL was also reduced, as were the number of eosinophils in the BAL 384	
and lung, with the reduction in eosinophils consistent with a recent study exploring the roles of 385	
TSLP, IL-25, and IL-33 in a model of chitin-induced lung inflammation (57).  We also observed 386	
marked and highly significant reductions in IL-5 and IL-13 production in the lung and BAL 387	
fluid.  When the combined mAb blockade of TSLP, IL-25, and IL-33 was applied to a model of 388	
established allergic lung inflammation, the marked protective effects were almost completely 389	
lost, however, suggesting that TSLP, IL-33, and IL-25 are either not required for the 390	
maintenance of an established antigen-specific type 2 response or that earlier intervention with 391	
TSLP, IL-33, and IL-25 antagonists is needed. 392	
 Although TSLP, IL-33, and IL-25 were all initially identified as critical drivers of type 2 393	
immunity (10, 12, 50), several subsequent studies have illustrated that type 2 immunity can 394	
develop independently of these cytokines (24-26, 28). The results from our experiments suggest 395	
that much of the data in the latter studies are likely explained by the overlapping activities of 396	
TSLP, IL-33, and IL-25.  Our data also suggest the three alarmins may be dispensable for the 397	
maintenance of type 2 immunity and chronic type 2-associated pathology because continued 398	
exposure to complex antigens like schistosome eggs or house dust mite allergen generates a 399	
potent and sustained adaptive CD4+ type 2 response that can supplant the requirement for 400	
alarmins and innate lymphocytes.  A recent double-blind, placebo-controlled study of AMG 157, 401	
a neutralizing anti-human TSLP mAb, showed that TSLP blockade could reduce allergen-402	
induced bronchoconstriction and eosinophilia (58). Whether targeting TSLP alone would show 403	
clinical benefit in moderate-severe asthma, however, could not be discerned from this small 404	
study tested on allergic individuals with near-normal baseline lung function.   405	
Differences in perturbations of epithelium and other stromal cells may dictate the relative 406	
contribution of the three alarmins, and further studies with different animal models of allergy 407	
(e.g. allergen dosing, variety, airway hypersensitivity) will be important before large-scale 408	
human studies are considered.  The cost and time required for chronic models prevented us from 409	
testing all combinations of single, double, and triple blockades in every model.  Notably, the 410	
triple blockade with mAbs from the start of allergic disease is effective, but its impact was not 411	
identical to congenital knockouts by all measures.  Although all three antibodies were confirmed 412	
to exhibit highly effective neutralizing activity, it is possible that incomplete target coverage with 413	
the antibodies might in part explain these differences as well as the minimal efficacy of treating 414	
mice with established allergic disease.  It is also possible that intracrine alarmin signaling such as 415	
IL-33-mediated activation of NF-κB contributes to these small differences.  In any case, antibody 416	
target coverage should be carefully evaluated in any future study in humans.  Chronic human 417	
disease is likely maintained by a complex assortment of signals combined with sporadic 418	
exposure to specific antigen, and a better understanding of the hierarchy of these cues will help 419	
to clarify the relative contributions of TSLP, IL-33, and IL-25, as well as ILC2s.  Our data 420	
suggest that a strategy that simultaneously suppresses more than one of these alarmins from the 421	
early phase of the disease may be required to effectively target type 2 cytokine-driven disease.  422	
 423	
Materials and Methods 424	
 425	
Study Design 426	
Our primary objective was to investigate the effects of ablating IL-33, TSLP, and IL-25 signaling 427	
on chronic type 2 inflammation and fibrosis.  To do this, we developed strategies to disrupt the 428	
signaling of the cytokines in mouse models of progressive type 2 immune-related pathology.  No 429	
statistical methods were used to predetermine sample size.  Group sample size was chosen using 430	
records of variance in past experiments, and variance is similar between groups being 431	
statistically compared.  Samples or data points were excluded only in the case of a technical 432	
equipment or human error that caused a sample to be poorly controlled for.  Mice or samples 433	
were randomly assigned to experimental groups or processing orders.  Group allocation was 434	
blinded for all mouse work, when possible (e.g. administration of proteins, schistosomes, or 435	
allergens, sample quantification and analysis, pathology scoring).  The ARRIVE guidelines in 436	
the EQUATOR Network library were followed for this report. 437	
 438	
Animals 439	
The National Institute of Allergy and Infectious Diseases Division of Intramural Research 440	
Animal Care and Use Program, as part of the National Institutes of Health Intramural Research 441	
Program, approved all of the experimental procedures (protocol “LPD 16E”).  The Program 442	
complies with all applicable provisions of the Animal Welfare Act 443	
(http://www.aphis.usda.gov/animal_welfare/downloads/awa/awa.pdf) and other federal statutes 444	
and regulations relating to animals.  IL-33–/– and IL-33/TSLP double knockout mice on a 445	
C57BL/6 background were provided by Amgen Inc.  C57BL/6, BALB/c, and IL-4Rα–/– mice 446	
were obtained from Taconic Farms Inc.  IL-25–/– mice were obtained from Regeneron 447	
Pharmaceuticals, Inc.  Male and female mice between the ages of 6 weeks and 12 weeks were 448	
used randomly to begin experimental models because of limited availability, and no sex-specific 449	
differences were observed.  Groups in individual experiments were sex-matched and age-450	
matched.  All animals were housed under specific pathogen-free conditions at the National 451	
Institutes of Health in an American Association for the Accreditation of Laboratory Animal 452	
Care-approved facility. 453	
 454	
Parasite infection 455	
Mice were infected percutaneously via the tail with 35 cercaria from a Puerto Rican strain of 456	
Schistosoma mansoni (NMRI) obtained from infected Biomphalaria glabrata snails (Biomedical 457	
Research Institute).  35 cercaria infection in wild-type mice leads to substantial disease and liver 458	
fibrosis but low mortality through the chronic phase of infection.  Mice were perfused at the time 459	
of euthanasia to determine worm and tissue egg burdens as described previously (59).   460	
 461	
Chronic house dust mite-induced allergy 462	
Mice anesthetized with isoflurane were challenged intranasally with 200 µg of house dust mite 463	
(HDM) in 30µl saline on days 0, 7, and 14 followed by eight additional 50 µg doses in 30µl 464	
saline spread over a total of 45 days. Lungs were harvested on day 46.   465	
 466	
Schistosome egg-induced lung granuloma models 467	
For the primary lung granuloma model, 5000 live S. mansoni eggs (Biomedical Research 468	
Institute) in saline were injected intravenously into mice on day 0.  Lungs were harvested on day 469	
7 for analysis.  For the secondary lung granuloma model, 5000 S. mansoni eggs were also 470	
injected intraperitoneally on day 0.  Mice were injected intravenously with 5000 live eggs 471	
containing mature embryos again on day 14 before lungs were harvested on day 21. 472	
 473	
Hydrodynamic delivery of IL-25  474	
Mice were injected intravenously with 10µg of a mammalian expression plasmid coding for 475	
murine IL-25 in 2ml of warm saline (60). 476	
 477	
Triple block of IL-33, TSLP, and IL-25 with monoclonal antibodies 478	
Anti-mouse ST2 (61), anti-mouse TSLP (38), and anti-mouse IL-25 (62) monoclonal antibodies 479	
were generated and selected by Amgen Inc. after extensive in vitro and in vivo testing.  480	
Previously unpublished tests for the efficacy of anti-TSLP included a bone marrow-derived 481	
dendritic cell bioassay measuring the inhibition of TSLP-induced CCL17/TARC production and 482	
an assay measuring inhibition of TSLP-induced proliferation of a pro-B cell line stably 483	
transduced with murine TSLP receptor.  Neutralization of IL-33, TSLP, and IL-25 signaling was 484	
achieved by administering 250μg of these antibodies, respectively, via intraperitoneal injection 485	
twice-weekly.  To properly control for the neutralizing antibodies, groups administered single 486	
and double blocks also received 250μg mouse IgG1 in the absence of anti-ST2 or anti-IL-25, and 487	
250Оg rat IgG1 in the absence of anti-TSLP. 488	
 489	
Histopathology  490	
Liver or lung tissue was fixed in Bouin-Hollande solution, embedded in paraffin for sectioning, 491	
and stained (Histopath of America) with Wright’s Giemsa (S. mansoni models), hematoxylin and 492	
eosin, or Masson’s trichrome (allergy model) for analysis of inflammation, picrosirius red or 493	
Masson’s trichrome for fibrosis analysis, or Periodic acid-Schiff (PAS) stain for analysis of 494	
mucus production.  A scale of 1 to 4 (4 being the highest) was used for scoring. A blinded 495	
pathologist measured the diameter of approximately 30 granulomas and quantified 496	
granulomatous eosinophils in Giemsa-stained sections of each sample with granulomatous 497	
pathology. Images were scanned with an Aperio ScanScope (Leica Biosystems). 498	
 499	
Fibrosis assay  500	
Hydroxyproline was measured as a surrogate for collagen content.  A known weight of liver or 501	
lung tissue was hydrolyzed in 6 N HCl at 110oC for 18 h and then neutralized in 10 N NaOH 502	
before colorization.  A standard curve comprised of dilutions of 1mM hydroxyproline (Sigma-503	
Aldrich) (63).  504	
 505	
Leukocyte isolation for intracellular cytokine staining and eosinophil identification  506	
About 200 mg of lung or liver tissue was ground into a single-cell suspension through a 100-µm 507	
nylon mesh. Leukocytes were separated on a 40% Percoll (Sigma-Aldrich) gradient (2000 rpm 508	
for 15 min) and treated for 2 min with 1 ml ACK (ammonium chloride–potassium bicarbonate) 509	
lysis buffer to lyse erythrocytes.  After 3 hours of stimulation with phorbol 12-myristate 13-510	
acetate (PMA 10ng/ml), ionomycin (1µg/ml), and Brefeldin A (BFA, 10µg/ml), leukocytes were 511	
fixed and permeabilized for 30 minutes (Cytofix/Cytoperm buffer; BD Biosciences) and then 512	
stained for 30 minutes with antibodies for CD4 (Clone: RM4-5; eBioscience), IFN-γ (XMG1.2, 513	
eBioscience), IL-4 (11B11, eBioscience), IL-5 (TRFK5, BD Pharmingen), and IL-13 (eBio13A, 514	
eBioscience) diluted in the Permwash buffer (BD Biosciences). Unstimulated lung leukocyte 515	
aliquots were set aside and stained for 30 minutes with anti-SiglecF. Postive SiglecF staining and 516	
scatter profiling were used to identify eosinophils by flow cytometry. Leukocytes collected from 517	
bronchoalveolar lavage were isolated with ACK lysis buffer, stimulated, fixed, permeabilized, 518	
and stained as above. Expression of CD4, SiglecF, and the intracellular cytokines was analyzed 519	
with a BD FACSCanto II flow cytometer and FlowJo v.7.6 software (Tree Star). 520	
 521	
Leukocyte isolation from liver and mesenteric lymph node for ILC2 staining  522	
Liver or lymph node tissue was ground into a single-cell suspension through a 100-µm nylon 523	
mesh, and hepatic leukocytes required further separation using a 40% Percoll gradient and ACK 524	
lysis as described above.  Leukocyte samples from both tissues were stimulated, fixed, and 525	
permeabilized as described above.  Then they were stained for 30 minutes with antibodies for 526	
CD16/32 (Clone: 2.4G2, BDBiosciences), CD4 (RM4-5, eBioscience), IL-13 (eBio13A, 527	
eBioscience), ST2 (DJ8, MD Biosciences), and ICOS (C398.4A, Biolegend) diluted in 528	
Permwash buffer (BD Biosciences).  Expression of the surface markers and intracellular IL-13 529	
was analyzed with a BD FACSCanto II flow cytometer and FlowJo v.7.6 software (Tree Star). 530	
 531	
RNA isolation and quantitative real-time PCR  532	
Lung or liver tissue was homogenized in TRIzol Reagent (Life Technologies) using Precellys 24 533	
(Bertin Technologies). Total RNA was extracted from the homogenate by addition of chloroform 534	
followed by the recommendations of the MagMax-96 Total RNA Isolation Kit (Life 535	
Technologies).  RNA was then reverse transcribed using SuperScript II Reverse Transcriptase 536	
(Life Technologies).  Real-time RT-PCR was performed on an ABI Prism 7900HT Sequence 537	
Detection System (Applied Biosystems). Quantities of mRNA expressed by a particular gene 538	
were determined using Power SYBR Green PCR Master Mix (Applied Biosystems), normalized 539	
to ribosomal protein, large, P2 (RPLP2) mRNA levels in each sample, and then articulated as a 540	
relative increase or decrease compared with mRNA levels expressed by the same gene in naive 541	
controls.  Primers were designed using Primer Express software (version 2.0; Applied 542	
Biosystems). Forward and reverse primer sequences are listed in Table S1. 543	
 544	
Bronchoalveolar lavage, cell differential determination, and ELISA 545	
1 ml of ice-cold PBS supplemented with 5mM EDTA was injected through the trachea into the 546	
lungs and aspirated using a syringe. ~1x105 cells were spun for 5 mins with a Shandon Cytospin 547	
3 centrifuge (Thermo Scientific) onto a slide before being fixed with methanol and stained with 548	
Diff-Quik (Boehringer) to identify leukocyte cell-types.  Levels of IL-4, IL-5, and IL-13 in the 549	
undiluted BAL were quantified using a Luminex-based multiplex assay according to 550	
manufacturer’s protocol (EMDMillipore). 551	
 552	
Statistical analysis  553	
All data were analyzed with Prism (Version 5; GraphPad). Data sets were compared with a two-554	
tailed t-test, and differences were considered significant if P values were less than 0.05.  A 555	
Welch’s correction was used when an F-test comparing variances had a P value of less than 0.05. 556	
 557	
Supplementary Materials 558	
Fig. S1. Alarmin gene expression in the liver. 559	
Fig. S2. Kinetics of alarmin gene expression in chronic HDM model. 560	
Fig. S3. Neutralizing all three alarmins with mAbs during initiation and maintenance of type 2-561	
driven allergy reduces inflammation and fibrosis. 562	
Table S1. qPCR Primer Sequences. 563	
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Figures Legends 787	
 788	
Figure 1. Ablating IL-25 offers no protection against type 2-mediated pathology.   789	
A. Quantitative PCR analysis of gene expression in lung and liver tissue from wild type 790	
C57BL/6 mice seven days after hydrodynamic injection of IL-25 (n = 5 mice) or PBS (n = 2). B. 791	
Histopathology analysis of livers from wild type and IL-13RГ1–/– mice seven days after S. 792	
mansoni egg exposure and 8 days after hydrodynamic injection of IL-25 or PBS (n = 12-15 per 793	
group; pooled from two independent experiments; scale bars=50μm). C. Cytokine quantification 794	
from bronchoalveor lavage fluid (BALF) of mice in B (n = 4-5 per group).  D. Histopathology 795	
analysis of lungs from IL-25–/– mice and littermate controls 7 days after challenge with S. 796	
mansoni eggs with (2o) or without priming (1o) with 5000 S. mansoni eggs 14 days prior to 797	
challenge (granuloma volume 1o: n = 18-23 per genotype pooled from three experiments; 798	
granuloma volume 2o: n = 9-10 per genotype pooled from two experiments; eosinophils: n = 5 799	
per genotype).  E. Histopathology analysis and fibrosis quantificiation of livers of IL-25–/– mice 800	
and littermate controls 12 weeks after infection with S. mansoni cercariae (n = 9 per genotype). 801	
A Student’s t-test was used to measure all P values, and P>0.05 except where reported.  Error 802	
bars represent standard error of the mean and each data point represents a value for an individual 803	
mouse.  Data are representative of two independent experiments unless otherwise noted. 804	
 805	
Figure 2. Ablating IL-33 offers no protection against type 2-mediated pathology. 806	
A. Fibrosis quantification and histopathology analysis of lungs from wild type C57BL/6 and IL-807	
33–/– mice 7 days after challenge with S. mansoni eggs (n = 7-10 per genotype). B. Fibrosis 808	
quantification and histopathology analysis of lungs of the same mouse strains 21 days after 809	
priming with S. mansoni eggs and 7 days after challenge with eggs (n = 10 per genotype).  C. 810	
Fibrosis quantification of livers from the same mouse strains infected with S. mansoni cercariae 811	
(n = 7-10 per genotype). D. Micrographs of representative liver tissue sections of mice in C 812	
collected 9 weeks after infection and stained with picrosirius red (scale bar=100μm).  E.  813	
Histopathology analysis of livers from the mice in C (n = 7-10 per genotype).  F.  Intracellular 814	
cytokine analysis of lymphocytes isolated from livers of mice in C nine weeks after infection 815	
measured by flow cytometry (n = 8 per genotype).  A Student’s t-test was used to measure all P 816	
values, and P>0.05 except where reported.  Data are representative of two independent 817	
experiments for each of the models. 818	
 819	
Figure 3. Disruption of all three mediators simultaneously has a transient effect on Th2 820	
pathology driven by S. mansoni. 821	
A. Granuloma measurement (n = 14-19 per group pooled from two independent experiments) 822	
from livers of S. mansoni-infected wild type C57BL/6 mice administered isotype control 823	
antibody and IL-33/TSLP double knockout (DKO) mice administered anti-IL-25. B. Fibrosis 824	
quantification from livers of infected mice (n = 7-10 per group).  C. Quantification of granuloma 825	
eosinophils from livers of infected mice (n = 7-9 per group).  D. Quantification of CD4–IL-13–826	
ST2+ICOS+ leukocytes from the mesenteric lymph nodes (MLNs; n = 7 per group) and livers 827	
(week 9: n = 7-8 per group; week 12: n = 14-15 per group pooled from two independent 828	
experiments) of infected mice by flow cytometry.  E. Micrographs of representative liver tissue 829	
sections of mice 12 weeks after infection and stained with picrosirius red (scale bar=500μm). F. 830	
Intracellular cytokine analysis of liver lymphocytes of infected mice by flow cytometry (n = 14-831	
17 per genotype pooled from two experiments). A Student’s t-test was used to measure all P 832	
values, and P>0.05 except where reported.  Data are representative of two independent 833	
experiments. 834	
 835	
Figure 4. Combined TSLP, IL-25, and ST2 mAb blockade during granuloma generation 836	
diminishes type 2 immunity but not pathology. 837	
A. Histopathology analysis of wild type BALB/c and IL-4R–/– mice seven days after injection 838	
with S. mansoni eggs.  Wild type egg-injected mice were either intraperitoneally (IP) 839	
administered anti-ST2,  anti-TSLP, and anti-IL-25, or corresponding isotype control antibodies 840	
(n = 8-9 per group).  Micrographs are of representative lung sections stained with Masson’s 841	
trichrome (scale bars = 50 μm). C. Quantification of gene expression in lung tissue from mice in 842	
A assayed by qPCR and shown relative to expression in lungs of naïve BALB/c mice (n = 3). B. 843	
Histopathology analysis of wild type BALB/c and IL-4R–/– mice seven days after injection with 844	
S. mansoni eggs and 21 days after priming with S. mansoni eggs (Isotypes IP, Triple block IP: n 845	
= 8-9 per group; IL-4R–/–: n = 5). Wild type egg-injected mice were either intraperitoneally 846	
administered anti-ST2, anti-TSLP, and anti-IL-25, or corresponding isotype control antibodies 847	
for all three weeks.  Micrographs are of representative lung sections stained with Masson’s 848	
trichrome (scale bars = 50 μm). D. Quantification of gene expression in lung tissue from mice in 849	
B assayed by qPCR and compared to a different group of naïve BALB/c controls (n = 3). A 850	
Student’s t-test was used to measure all P values, and P>0.05 except where reported. Data are 851	
representative of two independent experiments. 852	
 853	
Figure 5. Efficacy of TSLP, IL-25, and ST2 mAb blockade on established chronic allergy. 854	
Wild type BALB/c mice were sensitized and challenged intranasally with house dust mite 855	
(HDM), and starting on day 21, anti-ST2, anti-TSLP, and/or anti-IL-25 were administered in 856	
various combinations to different groups to achieve single, double, or triple blocks.  Additional 857	
control groups received only isotype control antibodies with or without HDM.  To properly 858	
control for the triple blockade group, groups administered single and double blocks also received 859	
IgG1 in the absence of anti-ST2 or anti-IL-25, and rat IgG1 in the absence of anti-TSLP.  All 860	
mice were analyzed on day 46.  A. Histopathology analysis of lung sections stained with 861	
Masson’s trichrome and scored for peribronchial and perivascular inflammation (n = 6-10 per 862	
group pooled from two experiments). B. Quantification of fibrosis from lung tissue.  C.  863	
Quantification of gene expression from lung tissue measured by qPCR. D. Quantification of 864	
leukocytes in the BALF and lung tissue. E. Quantification of eosinophils shown as a percentage 865	
of total inflammatory cells in BALF and lung tissue.  Student’s t-test was used to measure all P 866	
values, and P>0.05 except where reported. 867	
 868	
Figure 6. Disruption of all three mediators during initiation and maintenance of type 2-869	
driven chronic allergy reduces inflammation and fibrosis. 870	
Wild type C57BL/6 and IL-33/TSLP DKO mice were sensitized and challenged intranasally with 871	
HDM over 45 days. DKO mice were IP administered αIL-25 (DKO+αIL-25/HDM), and HDM-872	
treated wild-type C57BL/6 mice were IP administered an IgG1 isotype control (Isotype/HDM). 873	
A control group of C57BL/6 mice received intranasal saline instead of HDM and the isotype 874	
(Isotype/Saline). All mice were analyzed on day 46. A. Quantification of fibrosis from lung 875	
tissue (Isotype/Saline: n = 5; Isotype/HDM: n = 9; Triple block/Saline: n = 8). B. Histopathology 876	
analysis of lung sections stained with Masson’s trichrome for scoring of inflammation and AB-877	
PAS for mucus scoring. Micrographs are of representative lung sections stained with Masson’s 878	
trichrome (scale bars = 50 μm). C. Quantification of leukocytes in the BALF. D. BALF 879	
leukocyte differential. E. Quantification of eosinophils in lung tissue. F. Intracellular cytokine 880	
quantification of lung tissue lymphocytes by flow cytometry. G. Intracellular cytokine 881	
quantification of BALF lymphocytes by flow cytometry. A Student’s t-test was used to measure 882	
all P values, and P>0.05 except where reported. Data are representative of two independent 883	
experiments. 884	
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